PTC Therapeutics, Inc. v. AcureX Biosciences Corporation, et al.

• Court: District Court, N.D. California
• Decided: November 26, 2025
• Docket: 3:25-cv-04594
• Status: Unknown

Opinion

1 2 3 4 UNITED STATES DISTRICT COURT 5 NORTHERN DISTRICT OF CALIFORNIA 6 7 PTC THERAPEUTICS, INC., Case No. 25-cv-04594-AMO

8 Plaintiff, ORDER RE PLAINTIFF’S MOTION 9 v. TO DISQUALIFY

10 ACUREX BIOSCIENCES Re: Dkt. No. 45 CORPORATION, et al., 11 Defendants.

12 13 Plaintiff PTC Therapeutics, Inc. (“PTC”) asserts Defendants AcureX Biosciences 14 Corporation (“AcureX”), Dr. William Shrader, and Dr. Sean Pintchovski misappropriated trade 15 secrets regarding treatment of neurodegenerative diseases. On August 5, 2025, Defendants moved 16 to unseal the Complaint. (Dkt. No. 33.1) In support of their motion, Defendants submitted the 17 affidavit of Dr. Gladys Monroy, whom PTC contends had a prior attorney-client relationship with 18 BioElectron Technology Corporation (“BioElectron”), PTC’s predecessor-in-interest. (Dkt. No. 19 34-1.) PTC moves to strike the Monroy Affidavit, as well as disqualify both Dr. Monroy and 20 Cotchett, Pitre & McCarthy, LLP (“CPM”), counsel for Defendants. (Dkt. No. 45.) Defendants 21 oppose the motion. (Dkt. No. 57.) 22 Having considered the parties’ submissions, and with the benefit of oral argument heard on 23 November 20, 2025, the Court DENIES the motion to disqualify Dr. Monroy and CPM. The 24 Court also DENIES the motion to strike Dr. Monroy’s affidavit. 25 // 26 // 27 1 BACKGROUND 2 Drs. Shrader and Pintchovski initially worked for BioElectron (formerly known as “Edison 3 Pharmaceuticals, Inc.”), where they “played important roles in the research, development, and 4 characterization of the company’s lead compound, EPI-743, otherwise known as ‘Vatiquinone.’” 5 (Dkt. No. 2 ¶ 3.) “Vatiquinone can be used to inhibit 15-lipoxygenase (“15-LO”), an enzyme 6 involved in oxidative stress,” which in turn can “protect[] nerve cells and support[] their function 7 against neurodegenerative diseases like Friedreich’s ataxia and Parkinson’s disease.” (Id.) 8 Building on this research, Drs. Shrader and Pintchovski continued to work for BioElectron on the 9 development of a “second generation Vatiquinone,” ultimately known as EPI-857 (Utreloxastat). 10 (Id. ¶ 7.) 11 “In April 2019, PTC acquired substantially all BioElectron assets, including Vatiquinone 12 and EPI-857 (Utreloxastat).” (Id. ¶ 9.) PTC attaches a copy of the Asset Purchase Agreement that 13 facilitated this transaction, which describes the assets transferred. (Id. at 51, 109-11, 136.) , 14 BioElectron “agreed to sell, transfer, convey, assign and deliver to [PTC] substantially all of the 15 assets of [BioElectron], and [PTC] has agreed to assume certain of the liabilities of [BioElectron].” 16 (Id. at 136.) Schedule 3 to the Asset Purchase Agreement provides for the limited assets excluded 17 from the transaction:

18 All non-disclosure or confidentiality agreements, except for those agreements which include non-disclosure or confidentiality 19 obligations for the benefit of [BioElectron] relating to compound numbers EPI-743, EPI-589 and/or EPI-857. 20 All agreements with law firms (but not, for the avoidance of doubt, 21 any rights with respect to attorney client, work product or other privileges except to the extent relating solely to the negotiation of the 22 transactions contemplated by the Agreement), accounting firms, valuation firms and financial advisors. 23 All indemnification agreements with current or former officers or directors. 24 Exit Fee Agreement with Solar Capital dated August 10, 2018. 25 Letter of Credit with Bridge Bank N.A., dated November 23, 2009, as amended. 26 27 (Id. at 175.) Further, PTC acquired the right to hire any or all of BioElectron’s employees 1 of the Acquired Compounds,” terminable at will. (Id. at 97, 112.) The Agreement defines 2 “Acquired Compounds” to mean “the Product and all products, product candidates and 3 development candidates for which any member of the Seller Group [BioElectron] has conducted 4 research, development and/or commercialization activities and which are owned or controlled by 5 any member of the Seller Group [BioElectron], including those set forth on Schedule 2.” (Id. at 6 111.) Per Section 5.13 of the Agreement, BioElectron would maintain its corporate existence for a 7 period of 5 years following the transaction. (Id. at 98.) 8 Dr. Gladys Monroy was a patent attorney with the law firm Morrison & Foerster LLP, 9 during which time she was retained as IP counsel for BioElectron. (Dkt. No. 57-2 ¶ 5.) Between 10 2005 and 2015, she advised BioElectron “on all their IP matters, including patent filings for 11 compositions and methods that allegedly constitute trade secrets in this case.” (Id.) In preparing 12 her affidavit supporting Defendants’ motion to unseal the Complaint, Dr. Monroy relied upon 13 “materials that PTC publicly redacted and lodged under seal,” as well as her “decades of 14 experience as an IP attorney in the field of life sciences, and [her] familiarity with public sources 15 of information in the biotechnology and pharmaceutical fields.” (Id. ¶¶ 13-14.) Her conclusions 16 in the affidavit were based on “[her] training in biochemistry and molecular chemistry, [her] 17 extensive experience in the life sciences specifically related to these topics, and having advised 18 Edison/BioElectron with regards to their IP . . . .” (Id. ¶ 17.) 19 Dr. Monroy provided a second affidavit, filed in support of Defendants’ opposition to the 20 motion to disqualify. (Dkt. No. 57-3.) There, she states she does not have access to any of the 21 work she previously did for BioElectron, and she did not “review or rely on any confidential 22 information in forming or stating the opinion set forth in the Affidavit.” (Id. ¶¶ 2-3.) Prior to 23 reviewing the redacted portions of the Complaint, Dr. Monroy confirms she “executed an 24 Acknowledgment and Agreement to Be Bound (“Acknowledgment”), swearing under penalty of 25 perjury that [she] would keep the redacted portions of the complaint confidential.” (Id. ¶ 5.) 26 Moreover, she asserts she has not met with or communicated with any attorney from CPM 27 regarding the Complaint and has not shared any materials with the law firm. (Id. ¶¶ 6-7.) 1 under penalty of perjury, “[n]o attorney at CPM has ever spoken or otherwise communicated with 2 Dr. Monroy about this case (or, upon information and belief, about anything).” (Dkt. No. 57-1 3 ¶ 8.) He further attests that, “[o]ther than the Complaint, Dr. Monroy’s Affidavit (Ex. 1), Dr. 4 Monroy’s Second Affidavit (Ex. 2), and the signed Acknowledgment and Agreement to Be Bound 5 (Ex. 3) [CPM] has not exchanged any materials with Dr. Monroy.” (Id.) Per the declaration, 6 “Defendants have not and do not intend to retain Dr. Monroy as an expert witness at trial or with 7 respect to this case at large,” and CPM has met and conferred with Plaintiff’s counsel to confirm 8 there had been “no exchange of confidential information between Dr. Monroy and CPM.” 9 (Id. ¶¶ 11-12.) 10 LEGAL STANDARD 11 The power to disqualify an attorney for violation of their ethical responsibilities falls 12 within the discretion of the district court. See Gas-A-Tron of Arizona v. Union Oil Co. of 13 California, 534 F.2d 1322, 1324-25 (9th Cir. 1976). Any such motion to disqualify is governed by 14 the applicable state law. See In re Cnty. of Los Angeles, 223 F.3d 990, 995 (9th Cir. 2000) 15 (“Because we apply state law in determining matters of disqualification, we must follow the 16 reasoned view of the state supreme court when it has spoken on the issue.”). 17 Under California law, “‘an attorney is forbidden to do either of two things after severing 18 his relationship with a former client. He may not do anything which will injuriously affect his 19 former client in any [matter] in which he formerly represented him nor may he at any time use 20 against his former client knowledge or information acquired by virtue of the previous 21 relationship.’ . . . [T]he prohibition is in the disjunctive: [the attorney] may not use information or 22 ‘do anything which will injuriously affect his former client.’” Brand v. 20th Century Ins. Co./21st 23 Century Ins. Co., 124 Cal. App. 4th 594, 602 (2004) (quoting People ex rel. Deukmejian v. Brown, 24 29 Cal.3d 150, 155 (1981)) (alterations in original). “The scope of an attorney’s fiduciary duty 25 may be determined as a matter of law based on the Rules of Professional Conduct which, ‘together 26 with statutes and general principles relating to other fiduciary relationships, all help define the 27 duty component of the fiduciary duty which an attorney owes to his [or her] client.’” Metro- 1 denial of reh’g (Aug. 11, 1995) (quoting Stanley v. Richmond, 35 Cal.App.4th 1070, 1086-87 2 (1995)). The duty limiting such conflicts of interest was previously codified at Rule 3-310 of the 3 Rules of Professional Conduct, which has since been amended, and is now incorporated in Rules 4 1.7 and 1.9. Neither party argues the amendment materially changed the obligations set out in the 5 Rules, and so the Court relies upon interpretations of Rule 3-310 as well. 6 California courts deploy a “substantial relationship” test when determining whether an 7 attorney must be disqualified from a current representation adverse to a previous client. See 8 Brand, 124 Cal. App. 4th at 602. The test “turns on two variables: (1) the relationship between the 9 legal problem involved in the former representation and the legal problem involved in the current 10 representation, and (2) the relationship between the attorney and the former client with respect to 11 the legal problem involved in the former representation.” Id. at 603 (citing Jessen v. Hartford 12 Cas. Ins. Co., 111 Cal. App. 4th 698, 709 (2003)). As to this variable, the Court considers 13 whether “the relationship between the attorney and the former client is shown to have been 14 direct—that is, where the lawyer was personally involved in providing legal advice and services to 15 the former client . . . .” Id. at 604. If such a direct relationship existed, “then it must be presumed 16 that confidential information has passed to the attorney and there cannot be any delving into the 17 specifics of the communications between the attorney and the former client in an effort to show 18 that the attorney did or did not receive confidential information during the course of that 19 relationship.” Id. 20 DISCUSSION 21 PTC asserts Dr. Monroy must be disqualified as an expert based on her previous role as IP 22 counsel to BioElectron. (Dkt. No. 45 at 7-11.) Further, it argues the conflict of interest between 23 Dr. Monroy and PTC should be imputed to CPM, requiring disqualification of the firm as well. 24 (Id. at 12.) In opposition, Defendants contend Dr. Monroy’s duty to BioElectron did not transfer 25 to PTC and that no confidential information relevant to this case was transferred to Dr. Monroy. 26 (Dkt. No. 57 at 10-12.) As to disqualification of CPM, Defendants argue no fiduciary relationship 27 ever existed between PTC and CPM that would constitute a conflict of interest, so disqualification I. MOTION TO DISQUALIFY DR. MONROY AND COTCHETT, PITRE & 1 MCCARTHY, LLP 2 To determine whether Dr. Monroy violated the California Rules of Professional Conduct, 3 the Court must first determine whether the privilege passed from BioElectron to PTC as a 4 consequence of the 2019 Assert Purchase Agreement. 5 “. . . [W]hen control of a corporation passes to new management, the authority to assert 6 and waive the corporation’s attorney-client privilege passes as well.” Commodity Futures Trading 7 Comm’n v. Weintraub, 471 U.S. 343, 349 (1985). Certain corporate transactions or occurrences 8 may effect a transfer of the privilege to the successor. See, e.g., Weintraub, 471 U.S. at 349 9 (“New managers installed as a result of a takeover, merger, loss of confidence by shareholders, or 10 simply normal succession, may waive the attorney-client privilege with respect to communications 11 made by former officers and directors.”); see also Cal. Evid. Code § 953(d) (A holder of the 12 privilege may include: “[a] successor, assign, trustee in dissolution, or any similar representative 13 of a firm, association, organization, partnership, business trust, corporation, or public entity that is 14 no longer in existence.”). For instance, a corporate merger or bankruptcy may transfer the 15 privilege. See Dickerson v. Superior Ct., 135 Cal. App. 3d 93, 98 (1982); Weintraub, 471 U.S. at 16 358. That said, the California Court of Appeal has interpreted Section 953 of the Evidence 17 Code—which defines the holder of the privilege—narrowly. See Favila v. Katten Muchin 18 Rosenman LLP, 188 Cal. App. 4th 189, 219 (2010), as modified on denial of reh’g (Sept. 22, 19 2010). 20 In Favila v. Katten Muchin Rosenman LLP, the Court of Appeal considered whether the 21 attorney-client privilege had transferred from one corporation to another following an asset 22 transfer agreement. 188 Cal. App. 4th at 219-20. There, the predecessor corporation sold 100% 23 of its assets to the successor corporation via a Quitclaim Assignment. Id. at 200 n.3. A few 24 months after the asset transfer, the predecessor corporation dissolved. Id. at 201. Noting that 25 corporate mergers result in the transfer of the attorney-client privilege, the court distinguished 26 asset purchases. Id. at 219. Indeed, the court observed transfer of the privilege through an asset 27 purchase would contradict the language of Evidence Code Section 952, “which identifies the 1 corporation ‘is no longer in existence.’” Id. Consequently, the court held even a 100% asset sale 2 would not transfer the privilege to a purchaser corporation. Id. 3 Favila controls here. Though BioElectron transferred “substantially all of [its] assets” to 4 PTC, it did not transfer all of them. (Dkt. No. 2 at 136, 175.) Moreover, BioElectron was not 5 merged into PTC, as it was required to maintain its corporate existence for 5 years following the 6 transaction. (Id. at 98.) The Favila court recognized that even a 100% transfer of assets followed 7 by the dissolution of the predecessor corporation within two months did not result in transfer of 8 the privilege. 188 Cal. App. 4th at 219-20. Since the 2019 Asset Purchase Agreement between 9 BioElectron and PTC was not a merger, the attorney-client privilege held by BioElectron 10 regarding Dr. Monroy’s representation did not transfer to PTC. Absent an attorney-client 11 relationship between Dr. Monroy and PTC, there is no basis to disqualify Dr. Monroy and no basis 12 to impute a conflict of interest to CPM. 13 On reply, PTC does not address Favila; rather, it relies on a “practical consequences” test 14 for determining whether the attorney-client privilege transfers from a predecessor to a purchaser 15 corporation. (Dkt. No. 60 at 5.) In support of this test, PTC cites a number of district court 16 decisions, all of which either pre-date Favila or do not consider it. See Kadrey v. Meta Platforms, 17 Inc., No. 23-CV-03417-VC (TSH), 2024 WL 3913675, at *1 (N.D. Cal. Aug. 22, 2024) (did not 18 address Favila); STV Asia Ltd. v. PRN Corp., No. C-06-1664 JCS, 2006 WL 8460110, at *6 (N.D. 19 Cal. June 22, 2006) (decided before Favila); John Crane Prod. Sols., Inc. v. R2R & D, LLC, No. 20 3:11-CV-3237-D, 2012 WL 1694084, at *1 (N.D. Tex. May 15, 2012) (did not address California 21 law or Favila); UTStarcom, Inc. v. Starent Networks, Corp., No. CIV.A. 07-CV-2582, 2009 WL 22 4908579, at *3 (N.D. Ill. Feb. 20, 2009) (same); Array Holdings, Inc. v. Safoco, Inc., No. CV H- 23 12-0366, 2013 WL 12139272, at *2 (S.D. Tex. Jan. 30, 2013) (same). But the Court cannot ignore 24 decisions of the California Court of Appeal on matters of California state law. See Ogden Martin 25 Sys., Inc. v. San Bernardino Cnty. Cal., 932 F.2d 1284, 1288-89 (9th Cir. 1991) (“If no ruling 26 exists from the highest court of the state, [the federal court] must follow intermediate appellate 27 decisions unless convinced by other persuasive data that the highest court of the state would 1 predecessor corporation’s assets—does not transfer attorney-client privilege to the purchasing 2 entity. 3 PTC next argues the express terms of the 2019 Asset Purchase Agreement contemplate 4 transfer of the attorney-client privilege from BioElectron to PTC. (Dkt. No. 60 at 6.) Specifically, 5 Schedule 3 to the Agreement did not exclude the transfer of “any rights with respect to attorney 6 client, work product or other privileges except to the extent relating solely to the negotiation of the 7 transactions contemplated by the Agreement.” (Dkt. No. 2 at 175.) Yet PTC provides no 8 California legal authority to support its suggestion that a corporation can contractually assign the 9 attorney-client privilege to another corporation without merger of the two entities. As this is 10 PTC’s motion to disqualify counsel, it bears the burden of establishing appropriate grounds for 11 disqualification. See Bd. of Trs. of Leland Stanford Junior Univ. v. Zhang, 659 F. Supp. 3d 1061, 12 1067 (N.D. Cal. 2023) (citing H.F. Ahmanson & Co. v. Salomon Bros., Inc., 229 Cal. App. 3d 13 1445, 1452 (1991)) (“The party seeking disqualification bears the burden of establishing the 14 existence of a disqualifying conflict by a preponderance of the evidence.”). PTC has failed to do 15 so. 16 Lastly, PTC contends that even if the privilege did not transfer, it may still move for 17 disqualification based on its significant stake in any breach of a duty owed to BioElectron. (Dkt. 18 No. 60 at 7.) In support, PTC cites Concat LP v. Unilever, PLC, 350 F. Supp. 2d 796 (N.D. Cal. 19 2004), but the case is distinguishable. There, the district court considered whether Concat had 20 standing to bring a disqualification motion based on an attorney’s alleged breach of the duty of 21 loyalty to a non-party. Id. at 819. Law firm Morgan, Lewis represented the defendant, Unilever, 22 and also represented a non-party, which had a financial interest in Concat. Id. The court 23 determined Concat had Article III standing to bring the motion because the concurrent 24 representation of the non-party and Unilever breached the duty of loyalty, given the non-party’s 25 financial relationship with Concat. Id. However, Concat LP differs from the instant case because 26 PTC has not shown that BioElectron has any current stake in PTC. Moreover, the question of 27 “stake” goes to Article III standing to bring the disqualification motion; it does not, alone, 1 Monroy’s affidavit “so infects the litigation in which disqualification is sought that it impacts the 2 || moving party’s interest in a just and lawful determination of her claims.” Jd. at 818. 3 CONCLUSION 4 For the reasons stated above, PTC’s motion to disqualify Dr. Monroy and CPM as well as 5 || the motion to strike are DENIED. Further, the Court sets the hearing on Defendants’ motion to 6 || dismiss and motion to unseal the Complaint for January 20, 2026, at 2:00 p.m. 7 This Order disposes of Docket No. 45. 8 IT IS SO ORDERED. 9 Dated: November 26, 2025 10

ARACELI MARTINEZ-OLGUIN 12 United States District Judge

15 16

(«17

Z 18 19 20 21 22 23 24 25 26 27 28